ExonHit Announces the Inclusion of Proprietary Lead Compounds into Allergan Collaboration
News Feb 24, 2010
ExonHit Therapeutics has announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan
ExonHit Therapeutics has announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
"We are very fortunate to have a strong and productive partnership with Allergan, which allows both companies to take advantage of opportunities to shorten development timelines and rapidly move to create new shared products and value," stated Loic Maurel M.D., President of ExonHit Therapeutics' Management Board.
ExonHit will continue to lead the medicinal chemistry effort related to this target. The compounds are active against a new enzyme target potentially useful for therapeutic development in ophthalmology and neurodegenerative indications.
Milestone and royalty terms of the existing collaboration agreement will apply to these compounds and the products derived from them.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019